Free Trial
NASDAQ:ACHL

Achilles Therapeutics Q1 2024 Earnings Report

Achilles Therapeutics logo
$1.48 0.00 (0.00%)
As of 03/26/2025

Achilles Therapeutics EPS Results

Actual EPS
-$0.30
Consensus EPS
-$0.46
Beat/Miss
Beat by +$0.16
One Year Ago EPS
N/A

Achilles Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Achilles Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Wednesday, May 8, 2024
Conference Call Time
2:00AM ET

Upcoming Earnings

Achilles Therapeutics' next earnings date is estimated for Tuesday, May 6, 2025, based on past reporting schedules.

Earnings Documents

Achilles Therapeutics Earnings Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More Achilles Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Achilles Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Achilles Therapeutics and other key companies, straight to your email.

About Achilles Therapeutics

Achilles Therapeutics (NASDAQ:ACHL), a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

View Achilles Therapeutics Profile

More Earnings Resources from MarketBeat